Companies › Resilient Pharmaceuticals
1 active drug program in 20 registered trials: 12 Phase 2, 6 Phase 1, 2 Phase 3; Neurology, Oncology, Other, Psychiatry; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 1 | Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder … | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05783817 | Midomafetamine | Phase 2 | Obsessive-Compulsive Disorder | Psychiatry | Dec 2026 |
| NCT07584720 | Midomafetamine | Phase 1 | Healthy Volunteers | Other | Feb 2027 |
| NCT05770375 | Midomafetamine | Phase 1 | Schizophrenia | Psychiatry | Mar 2027 |
| NCT05770375 | Midomafetamine | Phase 1 | Schizophrenia | Psychiatry | Mar 2027 |
| NCT05770375 | Midomafetamine | Phase 1 | Schizophrenia | Psychiatry | Mar 2027 |
| NCT07494214 | Midomafetamine | Phase 1 | Healhty | Other | Mar 2027 |
| NCT06117306 | Midomafetamine | Phase 3 | Post-Traumatic Stress Disorder | Psychiatry | Mar 2027 |
| NCT07569159 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Apr 2027 |
| NCT05219175 | Midomafetamine | Phase 2 | Stress Disorders, Post-Traumatic | Psychiatry | Apr 2027 |
| NCT05837845 | Midomafetamine | Phase 2 | PTSD | Psychiatry | May 2027 |
| NCT05732155 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Jun 2027 |
| NCT06683014 | Midomafetamine | Phase 2 | Borderline Personality Disorder | Psychiatry | Jun 2027 |
| NCT07301632 | Midomafetamine | Phase 2 | Chronic Neuropathic Pain | Neurology | Dec 2027 |
| NCT06394284 | Midomafetamine | Phase 3 | PTSD, Post Traumatic Stress Disorder | Psychiatry | Dec 2027 |
| NCT05790239 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Mar 2028 |
| NCT06989957 | Midomafetamine | Phase 1 | Posttraumatic Stress Disorder | Psychiatry | Aug 2028 |
| NCT05584826 | Midomafetamine | Phase 2 | Cancer | Oncology | Nov 2028 |
| NCT06418178 | Midomafetamine | Phase 2 | Posttraumatic Stress Disorder | Psychiatry | Oct 2029 |
| NCT07288151 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Jan 2030 |
| NCT07118839 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | May 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.